after joining the study, you sign a consent form that explains the purpose, procedures, risks and benefits of the trial.

the study team records your medical history, performs a physical examination, takes blood samples, records vital signs, conducts an electrocardiogram (ecg) and obtains imaging scans to document the extent of metastatic prostate cancer.

the first dose of azd6621 is given by intravenous infusion, meaning the drug is delivered directly into a vein through a needle or catheter.

the exact amount, how often it is given and for how long are defined by the study protocol and may be adjusted during the trial.

after the infusion you are observed for a period of time while vital signs such as heart rate, blood pressure and breathing are checked for any immediate reactions.

at each scheduled visit you undergo blood tests, vital sign measurements, ecg and a physical exam to detect any adverse events or changes in laboratory values.

any side effects are recorded and reported to the study investigators.

in the early part of the trial (part a) the dose of azd6621 may be increased stepwise to find the highest dose that can be given safely.

if a dose limiting toxicity (a side effect that prevents further dose increase) occurs, the dose may be reduced or the treatment schedule may be changed.

you receive additional intravenous infusions of azd6621 according to the schedule defined by the protocol, which may be weekly or every few weeks.

each infusion is followed by the same safety monitoring described above.

periodically, blood is drawn to measure the level of psa (prostate‑specific antigen), a marker that indicates disease activity.

imaging studies are repeated to assess any changes in tumor size according to standard criteria.

if the trial moves to the expansion part, you continue receiving azd6621 at the dose identified as appropriate, while further data on anti‑tumor activity are collected.

treatment may stop if a serious side effect occurs, if the disease progresses, or when the planned number of treatment cycles is completed.

after the last infusion you undergo a final set of safety and efficacy assessments, including blood tests, vital signs, ecg and imaging, to document the overall outcome of the trial.